Mia's Feed
Medical News & Research

Multisociety Calls for Enhanced Infection Prevention and Control in Healthcare Facilities

Multisociety Calls for Enhanced Infection Prevention and Control in Healthcare Facilities

Share this article

2 min read

A coalition of leading healthcare organizations, including the Society for Healthcare Epidemiology of America (SHEA), the Association for Professionals in Infection Control and Epidemiology (APIC), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS), has issued a comprehensive joint position paper emphasizing the need to strengthen infection prevention and control (IPC) programs within U.S. healthcare facilities. Despite substantial progress over the years in reducing healthcare-associated infections (HAIs), the COVID-19 pandemic highlighted ongoing vulnerabilities and resource gaps in IPC efforts, underscoring the urgent necessity for more robust and well-funded programs.

The position paper advocates for healthcare leaders, regulatory agencies, and payers to treat IPC as a foundational element of healthcare delivery. Dr. Tom Talbot, Past President of SHEA and lead author, emphasized that infection prevention is essential for patient safety, quality care, and operational stability. The document outlines a clear roadmap to transform IPC programs into proactive, effectively resourced entities that can significantly reduce preventable harms.

Key recommendations include prioritizing comprehensive risk management in infection control, establishing direct access of IPC program leaders to senior management for swift support, and incorporating evaluations of leadership and resource allocation into facility surveys by regulatory bodies. The paper criticizes current regulatory standards, such as those from CMS, for lacking precise measures of program effectiveness, which often results in minimum compliance rather than genuine improvement.

To address these issues, the authors propose adopting a dyad leadership model — pairing a Medical Director of IPC with an Infection Preventionist Director of IPC — to foster better communication, collaboration, and strategic planning. They also call for revised standards that promote continuous improvement, data-driven interventions, and measurable outcomes.

Prioritizing effective IPC programs not only enhances patient safety but also offers financial benefits by reducing healthcare costs related to preventable infections. The Society emphasizes that investing in robust IPC infrastructure and leadership is crucial for maintaining trust, improving health outcomes, and ensuring a resilient healthcare system.

Future initiatives will focus on equipping healthcare facilities with the necessary tools and training to implement these best practices, ultimately elevating infection control standards nationwide.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

RFK Jr. Dismisses Entire US Vaccine Advisory Panel Over Alleged Conflicts of Interest

US Health Secretary RFK Jr. has dismissed the entire vaccine advisory panel over conflicts of interest, raising concerns about vaccine safety and independence. This move sparks debate on trust and transparency in public health decisions.

Addressing Knowledge Gaps in Perinatal Palliative Care Amidst Changing Abortion Laws

A new review reveals significant gaps in the evidence supporting perinatal palliative care in the U.S., emphasizing the need for more research amidst increasing legal restrictions on abortion.

Innovative Personalized Electrical Therapies Show Promise for Spinal Cord Injury Treatment

Emerging personalized electrical stimulation therapies offer new hope for improved recovery and motor function in spinal cord injury patients, highlighting the importance of tailored neurostimulation approaches.

Innovative Molecular Degraders Offer New Hope for Aggressive Breast Cancer Treatment

Scientists have developed innovative molecular degraders that target the 'undruggable' RNA-binding protein HuR, offering promising new treatments for aggressive breast cancer and other diseases.